NewsRelease
ResearchArticles Cites HemogloBind™ to Remove Analytical Interference fromAbdominal Aorta Lysates
MONMOUTHJUNCTION, NJ, December13, 2023 -- Biotech Support Group reports on a journal articledescribing the simplicity and efficiency of HemogloBind™, to removeHemoglobin interferences prior to analysis.
Jara,Zaira Palomino, et al. "DistinctMechanisms of β-Arrestin–Biased Agonist and Blocker of AT1R inPreventing Aortic Aneurysm and AssociatedMortality." Hypertension 80.2(2023): 385-402.
Aorticaneurysm (AA) is a “silent killer” human disease with noeffective treatment. Although the therapeutic potential of variouspharmacological agents have been evaluated, there are no reports ofβ-arrestin–biased AT1R (angiotensin II type-1 receptor) agonist(TRV027) used to prevent the progression of AA. The article states“Cleaned abdominal aortas were homogenized in T-PER Tissue ProteinExtraction reagent…. Abdominal aneurysm samples were treated toremove hemoglobin captured within the vessel wall. NuGel-HemogloBind… was used according to the manufacturer protocol. …To quantifythe puromycin incorporation, a standard Western blot was performed”.The article concludes TRV027-engaged AT1R prevented AA and associatedmortality by distinct molecular mechanisms compared with the AT1Rblocker, Olmesartan. Developing novel β-arrestin–biased AT1Rligands may yield promising drugs to combat AA.
“Allof our products are species agnostic, as they not derived fromimmuno-affinity, so they work for all species to the best of ourknowledge. Here in this example, for mice aorta lysates, HemogloBind™improves Western blot analysis by removing Hemoglobin as aninterfering component.” statesSwapan Roy, Ph.D., President and Founder of Biotech Support Group.
Clickhere for more information on HemogloBind™
Clickhere for more information on all of our Hemoglobin Removal products
Keywords:Hemoglobindepletion, HemogloBind™, aorticaneurysm, β-arrestin–biased ligand, AT1R
AboutBiotech Support Group LLC
Convergingwith cultural and technological disruptions forthcoming inhealthcare, Biotech Support Group develops methods for cost effectiveand efficient sample prep essential for expanding proteomic analysis.Following a tiered business strategy, the company continues itsgrowth in the consumable research products area. For this market, keyproducts include: AlbuVoid™ and AlbuSorb™ PLUS foralbumin & IgG depletion, Cleanascite™for lipid adsorption, HemogloBind™ and HemoVoid™ for hemoglobinremoval, and NRicher™ for low abundance and family specificproteome enrichment. For more information, go tohttp://www.biotechsupportgroup.com
Forbusiness development contact: MatthewKuruc
732-274-2866[email protected]